PHARMACOECONOMIC ASSESSMENT OF APIXABAN VERSUS STANDARD OF CARE FOR THE PREVENTION OF STROKE IN ITALIAN NON-VALVULAR ATRIAL FIBRILLATION PATIENTS
.
 The incremental cost effectiveness ratios (ICERs) of apixaban compared to warfarin and aspirin were € 5,607 and € 6,794 per QALY gained, respectively [ Tables I and II] .
 DSAs indicated that results were most sensitive to variations of the absolute risk reduction for cardiovascular events with apixaban [ Figures 3 ).
 The PSA substantially confirms the findings of the main analysis (Figure4). The probability of apixaban being cost-effective relative to warfarin and aspirin is 93% and 95%, respectively, for a WTP threshold of € 20,000 per QALY gained.
Results
 The objective of this study was to evaluate the cost-effectiveness of apixaban in the prevention of thromboembolic events in NVAF patients relatively to standard of care (warfarin or aspirin) from the Italian National Health System (SSN) perspective. 
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